Journal article Open Access

DESIGN & MOLECULAR DOCKING STUDIES OF COUMARIN SUBSTITUTED 1, 3, 4-OXADIAZOLES AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS.

Purohit S.S.*, Kulkarni V.H., Joshi S.D.


DCAT Export

<?xml version='1.0' encoding='utf-8'?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:adms="http://www.w3.org/ns/adms#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dct="http://purl.org/dc/terms/" xmlns:dctype="http://purl.org/dc/dcmitype/" xmlns:dcat="http://www.w3.org/ns/dcat#" xmlns:duv="http://www.w3.org/ns/duv#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:frapo="http://purl.org/cerif/frapo/" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:gsp="http://www.opengis.net/ont/geosparql#" xmlns:locn="http://www.w3.org/ns/locn#" xmlns:org="http://www.w3.org/ns/org#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:prov="http://www.w3.org/ns/prov#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:schema="http://schema.org/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:vcard="http://www.w3.org/2006/vcard/ns#" xmlns:wdrs="http://www.w3.org/2007/05/powder-s#">
  <rdf:Description rdf:about="https://doi.org/10.5281/zenodo.3864857">
    <dct:identifier rdf:datatype="http://www.w3.org/2001/XMLSchema#anyURI">https://doi.org/10.5281/zenodo.3864857</dct:identifier>
    <foaf:page rdf:resource="https://doi.org/10.5281/zenodo.3864857"/>
    <dct:creator>
      <rdf:Description>
        <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Agent"/>
        <foaf:name>Purohit S.S.*, Kulkarni V.H., Joshi S.D.</foaf:name>
        <foaf:givenName>Kulkarni V.H., Joshi S.D.</foaf:givenName>
        <foaf:familyName>Purohit S.S.*</foaf:familyName>
        <org:memberOf>
          <foaf:Organization>
            <foaf:name>S.E.T.'s College of Pharmacy, S. R. Nagar, Near Microwave Tower, Dharwad-580002.</foaf:name>
          </foaf:Organization>
        </org:memberOf>
      </rdf:Description>
    </dct:creator>
    <dct:title>DESIGN &amp; MOLECULAR DOCKING STUDIES OF COUMARIN SUBSTITUTED 1, 3, 4-OXADIAZOLES AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS.</dct:title>
    <dct:publisher>
      <foaf:Agent>
        <foaf:name>Zenodo</foaf:name>
      </foaf:Agent>
    </dct:publisher>
    <dct:issued rdf:datatype="http://www.w3.org/2001/XMLSchema#gYear">2020</dct:issued>
    <dcat:keyword>GSK-3 Inhibitors, Coumarin Containing 1,3, 4-Oxadiazoles, Design &amp; Molecular Docking.</dcat:keyword>
    <dct:issued rdf:datatype="http://www.w3.org/2001/XMLSchema#date">2020-05-29</dct:issued>
    <owl:sameAs rdf:resource="https://zenodo.org/record/3864857"/>
    <adms:identifier>
      <adms:Identifier>
        <skos:notation rdf:datatype="http://www.w3.org/2001/XMLSchema#anyURI">https://zenodo.org/record/3864857</skos:notation>
        <adms:schemeAgency>url</adms:schemeAgency>
      </adms:Identifier>
    </adms:identifier>
    <dct:isVersionOf rdf:resource="https://doi.org/10.5281/zenodo.3864856"/>
    <dct:isPartOf rdf:resource="https://zenodo.org/communities/iajpr"/>
    <dct:description>&lt;p&gt;Glycogen synthase kinase 3 (GSK-3) is a &lt;a href="http://en.wikipedia.org/wiki/Serine/threonine_protein_kinase"&gt;serine/threonine protein kinase&lt;/a&gt; that mediates the addition of phosphate molecules onto &lt;a href="http://en.wikipedia.org/wiki/Serine"&gt;serine&lt;/a&gt; and &lt;a href="http://en.wikipedia.org/wiki/Threonine"&gt;threonine&lt;/a&gt; amino acid residues. First discovered in 1980 as a regulatory kinase for its namesake, &lt;a href="http://en.wikipedia.org/wiki/Glycogen_synthase"&gt;Glycogen synthase&lt;/a&gt;, GSK-3 has since been identified as a kinase for over forty different proteins in a variety of different pathways. GSK-3 has recently been the subject of much research because it has been implicated in a number of diseases, including Type II diabetes (&lt;a href="http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2"&gt;Diabetes mellitus type 2&lt;/a&gt;), &lt;a href="http://en.wikipedia.org/wiki/Alzheimer%27s_Disease"&gt;Alzheimer&amp;#39;s Disease&lt;/a&gt;, &lt;a href="http://en.wikipedia.org/wiki/Inflammation"&gt;inflammation&lt;/a&gt;, &lt;a href="http://en.wikipedia.org/wiki/Cancer"&gt;cancer&lt;/a&gt;, and &lt;a href="http://en.wikipedia.org/wiki/Bipolar_disorder"&gt;bipolar disorder&lt;/a&gt;. A plethora of GSK-3 inhibitors has been described and most of the effects were observed in vitro and cellular studies. Present study is aimed at design of GSK-3 Inhibitors, their molecular docking studies using online molecular docking software, i.e. www. Dockingserver.com. Based upon previous studies on 1, 3, 4-oxadiazoles as GSK-3 inhibitors, 1, 3, 4-oxadiazole molecule skeleton was taken as the core skeleton &amp;amp; 4 different modifications were made. The compounds were docked with GSK (PDB ID: 3f88 and PDB ID: 4E7W).The results have shown appreciable molecular docking interactions with the GSK-3 protein amino acid residues. The Est. inhibition constant, Ki values for the ligands were observed in &amp;micro;M values. . It is observed that Ligand I has shown Est. free energy of binding -10.17 which is said to be better than the other 3 ligands &amp;amp; reference ligands.&lt;/p&gt;</dct:description>
    <dct:accessRights rdf:resource="http://publications.europa.eu/resource/authority/access-right/PUBLIC"/>
    <dct:accessRights>
      <dct:RightsStatement rdf:about="info:eu-repo/semantics/openAccess">
        <rdfs:label>Open Access</rdfs:label>
      </dct:RightsStatement>
    </dct:accessRights>
    <dct:license rdf:resource="https://creativecommons.org/licenses/by/4.0/legalcode"/>
    <dcat:distribution>
      <dcat:Distribution>
        <dcat:accessURL rdf:resource="https://doi.org/10.5281/zenodo.3864857">https://doi.org/10.5281/zenodo.3864857</dcat:accessURL>
        <dcat:byteSize>1589412</dcat:byteSize>
        <dcat:downloadURL rdf:resource="https://zenodo.org/record/3864857/files/200306 ready.pdf">https://zenodo.org/record/3864857/files/200306 ready.pdf</dcat:downloadURL>
        <dcat:mediaType>application/pdf</dcat:mediaType>
      </dcat:Distribution>
    </dcat:distribution>
  </rdf:Description>
</rdf:RDF>
54
27
views
downloads
All versions This version
Views 5454
Downloads 2727
Data volume 42.9 MB42.9 MB
Unique views 4545
Unique downloads 2525

Share

Cite as